Marketed & Developmental Products

The following table summarizes the status of products marketed, approved and/or under advanced development by Noven. Developmental products are identified in yellow.

Product

Indication

Regulatory Status

Marketing Rights

Noven Therapeutics

Daytrana®
(methylphenidate
transdermal system)

ADHD in children
6-17 years old		 Marketed in U.S.
Noven
Stavzor®
 (valproic acid delayed release capsules)		 Bipolar disorder, migraine & epilepsy Marketed in U.S. Noven

Pexeva®
 (paroxetine mesylate)

Depression, panic disorder, OCD & GAD Marketed in U.S. Noven
Lithobid®
 (lithium carbonate) 		Bipolar disorder Marketed in U.S. Noven
Mesafem™
 (low-dose paroxetine mesylate) 		Non-hormonal therapy for vasomotor symptoms Phase 3 Noven

Transdermal Hormone Therapy

Vivelle-Dot®/
Estradot®
(estradiol transdermal system)

Menopausal symptoms/
osteoporosis
Marketed in U.S. and abroad Novogyne1--U.S.
Sanofi-aventis--Japan
Novartis Pharma--all other territories

CombiPatch®/Estalis®
(estradiol / NETA transdermal system)

Menopausal symptoms Marketed in U.S. and abroad

Novogyne--U.S.
Sanofi-aventis--Japan
 Novartis Pharma--all other territories

Next Generation
Transdermal Estrogen

 Menopausal symptoms Clinical development

Novogyne--U.S.
Transdermal Pain Management  
Fentanyl Transdermal
System
 Persistent, moderate to severe chronic pain Marketed in U.S.

 Apotex Corp.--U.S.
Parent Company Collaboration
Multiple Undisclosed Projects
 Various Pre-clinical and clinical development
 Hisamitsu/Noven
1
 Novogyne Pharmaceuticals is a joint venture between Noven and Novartis Pharmaceuticals Corporation.

 

Copyright © 2012 Noven Pharmaceuticals, Inc. All rights reserved.